WO2023181844A1 - Inhibiteur d'infection virale, élément d'inhibition d'infection virale et peinture d'inhibition d'infection virale - Google Patents

Inhibiteur d'infection virale, élément d'inhibition d'infection virale et peinture d'inhibition d'infection virale Download PDF

Info

Publication number
WO2023181844A1
WO2023181844A1 PCT/JP2023/007992 JP2023007992W WO2023181844A1 WO 2023181844 A1 WO2023181844 A1 WO 2023181844A1 JP 2023007992 W JP2023007992 W JP 2023007992W WO 2023181844 A1 WO2023181844 A1 WO 2023181844A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymer compound
virus infection
virus
viral infection
mass
Prior art date
Application number
PCT/JP2023/007992
Other languages
English (en)
Japanese (ja)
Inventor
拓也 木下
大地 川村
洋平 西村
和也 西原
太郎 鈴木
Original Assignee
積水化学工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 積水化学工業株式会社 filed Critical 積水化学工業株式会社
Publication of WO2023181844A1 publication Critical patent/WO2023181844A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/34—Shaped forms, e.g. sheets, not provided for in any other sub-group of this main group
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/04—Nitrogen directly attached to aliphatic or cycloaliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N61/00—Biocides, pest repellants or attractants, or plant growth regulators containing substances of unknown or undetermined composition, e.g. substances characterised only by the mode of action
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/02—Compositions of unspecified macromolecular compounds characterised by the presence of specified groups, e.g. terminal or pendant functional groups

Definitions

  • the present invention relates to a virus infection inhibiting agent, a virus infection inhibiting member, and a virus infection inhibiting paint.
  • the highly pathogenic avian influenza virus has mutated and has been confirmed to infect humans, and there is also concern about the Sars virus, which has an extremely high mortality rate, and anxiety about the virus is only increasing.
  • Patent Document 1 proposes an antiviral synthetic resin composition containing 0.5 parts by mass or more of a sulfonic acid surfactant per 100 parts by mass of the synthetic resin.
  • the above-mentioned antiviral synthetic resin composition has a problem in that when it is used after being dispersed in a base material such as a paint or a synthetic resin, the surface of the base material becomes white.
  • the present invention provides a virus infection inhibitor that can generally prevent whitening of the surface of a substrate even when used in a substrate.
  • the virus infection inhibitor of the present invention has at least one amino group or a salt thereof selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group, and has a weight average molecular weight of 1000.
  • the main chain of the polymer compound contains no nitrogen atom.
  • the virus infection inhibiting member of the present invention is characterized by comprising a base material and the virus infection inhibiting agent according to any one of claims 1 to 7 contained in the base material.
  • the virus infection inhibitor of the present invention has the above-mentioned structure, it can generally prevent whitening of the surface of the base material even when it is used in a base material, and is an excellent virus infection inhibitor. It is possible to construct a virus infection prevention member that has an infection prevention effect and has an excellent appearance.
  • the virus infection inhibitor of the present invention has at least one amino functional group or a salt thereof selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group, and has a weight average molecular weight of 1000 or more, and the main chain of the polymer compound does not contain a nitrogen atom.
  • Viral infection inhibitors contain high molecular compounds as active ingredients.
  • the virus infection inhibitor has at least one amino functional group selected from the group consisting of a primary amino group, a secondary amino group and a tertiary amino group, or a salt thereof, and has a weight average molecular weight of 1000 or more.
  • the content of the polymer compound that does not contain nitrogen atoms in its main chain is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, and 80% by mass or more in the active ingredients. It is more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and even more preferably 100% by mass.
  • the virus infection inhibitor has at least one amino functional group selected from the group consisting of a primary amino group, a secondary amino group and a tertiary amino group, or a salt thereof, and has a weight average molecular weight of 1000 or more.
  • the content of the polymer compound that does not contain nitrogen atoms in its main chain is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, and 90% by mass or more. It is more preferably 95% by mass or more, more preferably 99% by mass or more, and even more preferably 100% by mass.
  • the polymer compound has at least one amino functional group or a salt of an amino functional group selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group.
  • the polymer compound is derived from at least one amino functional group or a salt of an amino functional group selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group, and has an excellent ability to inhibit virus infection. In particular, it has an excellent effect of inhibiting virus infection against non-enveloped viruses.
  • the amino functional group not only improves the virus infection inhibiting effect of the virus infection inhibitor, but also prevents whitening of the surface of the base material even when the base material contains the virus infection inhibiting effect. , preferably contains a secondary amino group. Furthermore, since the amino functional group has the effect of inhibiting virus infection against both enveloped viruses and non-enveloped viruses, it is preferable to include a secondary amino group.
  • the amino functional group not only improves the virus infection inhibiting effect of the virus infection inhibitor, but also prevents whitening of the surface of the base material even when the base material contains the virus infection inhibiting effect. , it is preferable that a cyclic skeleton is formed, and it is preferable that an alicyclic cyclic skeleton is formed.
  • the primary amino group means a monovalent substituent represented by -NH 2 .
  • a secondary amino group means a divalent substituent (-NH-) formed by removing (withdrawing) one hydrogen atom from -NH 2 .
  • a tertiary amino group means a trivalent substituent [ ⁇ N, formula (a)] formed by removing (extracting) two hydrogen atoms from -NH 2 .
  • the amino functional group excludes cases where a keto group (>CO) is directly bonded to the nitrogen atom constituting the amino functional group.
  • the salt of the amino functional group is not particularly limited, but acid addition salts are preferred.
  • acids for acid addition salts include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, and oleic acid.
  • the effect of inhibiting virus infection refers to the effect of eliminating or reducing the infectivity of a virus to cells, or preventing it from proliferating in cells even if infected.
  • methods for confirming the presence or absence of virus infectivity include ISO 18184 and JIS L1922 for textile products, and ISO 21702 for products with plastics and non-porous surfaces other than textile products.
  • Other methods include the plaque method and the hemagglutination titer (HAU) measurement method described in "Medical and Pharmaceutical Virology” (first edition published in April 1990).
  • the virus infection inhibiting effect of the virus infection inhibitor can be measured, for example, in the following manner.
  • a virus infection inhibiting paint is prepared by mixing 3 parts by mass of a virus infection inhibitor and 97 parts by mass of an ultraviolet curable acrylic paint.
  • a coating layer is formed by applying a virus infection inhibiting paint onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8.
  • the coating layer is irradiated with ultraviolet rays with a wavelength of 365 nm at a cumulative amount of 500 mJ/cm 2 at 25° C. to cure the ultraviolet curable acrylic paint to form a coating film with a thickness of 18 ⁇ m.
  • a test piece is prepared by cutting out a planar square shape with a side of 5.0 cm.
  • the surface of the coating film of the obtained test piece is wiped off using a square nonwoven fabric with a side of 10 cm by moving the nonwoven fabric back and forth 10 times to obtain a test coating film.
  • the obtained test coating film is subjected to an antiviral test in accordance with ISO21702.
  • the virus infectivity value (common logarithm value) (PFU/cm 2 ) of the test coating is calculated by the plaque method.
  • a blank coating film was prepared in the same manner as above except that no virus infection inhibitor was contained, and based on this blank coating, the virus infection titer (common logarithm value) (PFU/cm 2 ) was determined in the same manner as above. Calculate.
  • the antiviral activity value after 10 minutes from the start of the reaction in an antiviral test based on ISO21702 is preferably 0.6 or more, more preferably 1.0 or more, and even more preferably 2.0 or more.
  • the antiviral activity value after 24 hours from the start of the reaction in an antiviral test based on SO21702 is preferably 0.6 or more, more preferably 1.0 or more, and even more preferably 2.0 or more. . Regardless of the type of virus to be evaluated, it is preferable that the antiviral activity value is 0.6 or more for at least one type of virus.
  • a polymer compound having an amino functional group or a salt thereof has an amino functional group or a salt thereof in the side chain, but the main chain does not contain a nitrogen atom.
  • the main chain of a polymer compound is the longest chain in a polymer compound, and the length of the chain can be determined by the number of atoms contained in the chain. The more , the longer the chain is judged to be.
  • Atoms contained in the main chain refer to atoms that directly constitute the main chain. Therefore, for example, when a vinyl polymer constitutes a main chain, the main chain contains carbon atoms, but the hydrogen bonded to the carbon atoms is not included in the atoms directly forming the main chain. It is not included and is not contained in the main chain.
  • the polymer compound does not contain a nitrogen atom in its main chain.
  • the polymer compound may have 0 nitrogen atoms in its main chain.
  • the atoms constituting the main chain may be any atoms other than nitrogen atoms, such as carbon atoms, sulfur atoms, oxygen atoms, etc. Carbon atoms and sulfur atoms are preferred, and only carbon atoms or carbon atoms and sulfur atoms are preferred.
  • the polymer compound has an amino functional group or a salt thereof in the molecule.
  • examples of the polymer compound include polymers containing amino functional groups or salts thereof in the side chains of linear polymers.
  • the linear polymer is not particularly limited, and for example, vinyl polymers and polyesters are preferable, and vinyl polymers are more preferable.
  • polymers containing amino functional groups or salts thereof in the side chains of linear polymers include polymers containing amino functional group-containing monomers containing amino functional groups or salts thereof as monomer units.
  • the amino functional group-containing monomer containing an amino functional group or a salt thereof is not particularly limited, and examples thereof include 2-vinylpyridine, 4-vinylpyridine, vinylimidazole, dimethylaminoethyl (meth)acrylate, and (meth)acrylic acid. Obtained by reacting diethylaminoethyl acid, t-butylaminoethyl (meth)acrylate, N-(aminoalkyl)acrylamide, N-(aminoalkyl)methacrylamide, glycidyl (meth)acrylate with ammonia, dimethylamine, etc.
  • Monomers allylamine, diallylamine, methyldiallylamine, 1,2,2,6,6-pentamethyl-4-piperidyl methacrylate, 2,2,6,6-tetramethyl-4-piperidyl methacrylate or salts of these amino functional groups, etc. can be mentioned.
  • the amino functional group-containing monomer containing an amino functional group or a salt thereof may be used alone or in combination of two or more types.
  • n shows a repeating unit and is a natural number of 2 or more. n indicates a repeating unit, and it goes without saying that the n used in the general formula need not be the same.
  • the polymer containing an amino-functional group-containing monomer as a monomer unit may be a homopolymer of the amino-functional group-containing monomer, or a copolymer of the amino-functional group-containing monomer and a monomer copolymerizable therewith. .
  • Monomers copolymerizable with the amino functional group-containing monomer are not particularly limited, and include, for example, alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride. , 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyltoluene and the like.
  • the monomers copolymerizable with the amino functional group-containing monomer may be used alone or in combination of two or more.
  • the polymer compound preferably has a carboxy group or a salt thereof in the molecule, since this improves the virus infection inhibiting effect of the virus infection inhibitor.
  • Salts of carboxy groups are not particularly limited, and examples include potassium salts (-COOK), sodium salts (-COONa), calcium salts [(-COO - ) 2 Ca 2+ ], ammonium salts (-COO - NH 4 + ), magnesium salt [(-COO - ) 2 Mg 2+ ], barium salt [(-COO - ) 2 Ba 2+ ], and the like.
  • Examples of the polymer compound containing a carboxyl group include a polymer containing an amino functional group or a salt thereof and a carboxyl group or a salt thereof in the side chain of a linear polymer.
  • polymers containing an amino functional group or a salt thereof and a carboxy group or a salt thereof in the side chain of a linear polymer include an amino functional group-containing monomer containing an amino functional group or a salt thereof, and a carboxy group or a salt thereof.
  • examples include polymers containing a carboxy group-containing monomer containing the salt thereof as a monomer unit. Note that the amino functional group-containing monomer containing an amino functional group or a salt thereof is the same as described above, so a description thereof will be omitted.
  • Carboxy group-containing monomers containing a carboxy group or a salt thereof are not particularly limited, and examples thereof include acrylic acid, methacrylic acid, ⁇ -carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, and succinic acid mono( Examples include meth)acryloyloxyethyl ester, ⁇ -carboxypolycaprolactone mono(meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, carboxybetaine type monomers or salts thereof, and oxalic acid is preferred. .
  • the carboxy group-containing monomers may be used alone or in combination of two or more types.
  • a polymer compound containing an amino functional group or a salt thereof and a carboxy group may contain a repeating unit represented by the following formula (7). preferable.
  • the polymer compound may be polymerized using a general-purpose polymerization method.
  • a monomer composition containing an amino functional group-containing monomer containing an amino functional group or a salt thereof, and optionally a carboxyl group-containing monomer containing a carboxyl group or a salt thereof and other monomers can be used as a general-purpose radical.
  • a polymer compound can be obtained by polymerizing in the presence of a polymerization initiator.
  • a polymer compound can be obtained by polymerizing a monomer composition containing an amino functional group-containing monomer containing an amino functional group or a salt thereof and a monomer containing a hydroxyl group in the presence of a general-purpose radical polymerization initiator. You can.
  • radical polymerization initiator examples include thermally cleavable radical polymerization initiators such as 1-hydroxycyclohexane-1-ylphenyl ketone, t-hexyl peroxypivalate, benzoyl peroxide, and azobisisobutyronitrile. It will be done.
  • a polymer containing an amino functional group may be synthesized by a condensation reaction or transesterification reaction between a polymer having a hydroxyl group and a monomer containing an amino functional group.
  • the nitrogen atom content of the polymer compound is preferably 0.1% or more, more preferably 0.5% or more.
  • the nitrogen atom content of the polymer compound is preferably 50% or less, more preferably 45% or less, more preferably 40% or less, more preferably 35% or less, and even more preferably 30% or less.
  • whitening of the surface of the substrate can be generally prevented even when the substrate contains a virus infection inhibitor.
  • the nitrogen atom content (%) of a polymer compound refers to the percentage of the nitrogen atomic weight to the total atomic weight of the repeating units constituting the polymer compound.
  • n, m and p represent repeating units and are natural numbers of 2 or more.
  • Nitrogen atom content of polymer compounds 100 x ⁇ (Total nitrogen atomic weight contained in M 1 ) x m + (Total nitrogen atomic weight contained in M 2 ) x n ⁇ / ⁇ (Total atomic weight of M 1 ) x m + (Total atomic weight of M 2 ) x n ⁇
  • the structural formula shown in formula (8) means a random copolymer, alternating copolymer, or block copolymer of monomer units M1 and M2 .
  • the polymerization form of the polymer compound contained in the virus infection inhibitor is such that the charge states in the polymer chain are arranged in an average manner, and the surface of the polymer compound is in an appropriate charge state. Random copolymers are preferred because they improve the infection-inhibiting effect.
  • the weight average molecular weight of the polymer compound is preferably 1000 or more, more preferably 2000 or more, and even more preferably 3000 or more.
  • the polymer compound can interact with the virus at multiple points, and the virus infection prevention effect of the virus infection prevention member can be improved.
  • the weight average molecular weight of the polymer compound is preferably 1,000,000 or less, more preferably 900,000 or less, more preferably 800,000 or less, and more preferably 600,000 or less.
  • the weight average molecular weight of the polymer compound is 1,000,000 or less, whitening of the surface of the base material containing the virus infection inhibitor can be reduced, and the effect of inhibiting virus infection can be made more effective without impairing the appearance of the base material.
  • the aggregation of the virus infection-inhibiting compound is reduced, resulting in a form in which the virus-infection-inhibiting compound and the virus are likely to interact, and the virus infection-inhibiting effect of the virus infection-inhibiting agent is improved.
  • the weight average molecular weight of the polymer compound is the weight average molecular weight of the entire polymer compound.
  • the weight average molecular weight of the polymer compound is a value measured by GPC (gel permeation chromatography) in terms of polystyrene.
  • the measurement can be performed using the following measuring device and measurement conditions.
  • Gel permeation chromatograph Manufactured by Waters, product name “2690Separations Model”
  • Column Manufactured by Showa Denko, product name “GPCKF-806L”
  • Detector Differential refractometer Sample flow rate: 1mL/min
  • the pH of a 5% by mass aqueous solution of a polymer compound at 25°C is preferably 4 or less.
  • the pH of the 5% by mass aqueous solution of the polymer compound at 25° C. is preferably 9 or higher. If the pH of a 5% by mass aqueous solution of a polymer compound at 25°C is 4 or less, the surface of the polymer compound will be in an appropriate charge state, or the number of protons on the virus surface will increase, resulting in static interaction with the virus infection inhibitor. The electric interaction increases, and the virus infection inhibiting effect of the virus infection inhibitor improves.
  • the pH of a 5% by mass aqueous solution of a polymer compound at 25°C is 4 or less or 10 or more, the surface of the polymer compound becomes an appropriate charge state or the surface of the virus is anionized, thereby inhibiting virus infection.
  • the electrostatic interaction with the agent increases, and the infection inhibiting effect of the virus infection inhibitor improves.
  • the pH at 25° C. of a 5% by mass aqueous solution of a polymer compound refers to the pH value at 25° C. of a mixed solution in which 5 g of a polymer compound is added to 95 g of purified water and mixed uniformly.
  • the mixed liquid may be a saturated aqueous solution in which the entire amount of the polymer compound is dissolved in the purified water, or a portion of the polymer compound is dissolved in the purified water.
  • the pKa1 of the polymer compound at 25° C. is preferably 8 or more, more preferably 8.5 or more. If the pKa1 at 25°C of the polymer compound is 8 or more, the surface of the polymer compound will be in an appropriate charge state during the interaction between the polymer compound and the virus, and the virus will be effectively captured and the virus infection inhibitor will be effective. In addition to improving the virus infection inhibiting effect, whitening of the surface of the base material can be generally prevented even when the base material contains a virus infection inhibitor.
  • the pKa1 of the polymer compound at 25° C. is preferably 12 or less, more preferably 11 or less, and even more preferably 10 or less.
  • the acid dissociation constant Ka is defined by the equation (c)
  • pKa is the acid dissociation constant Ka It is defined as the common logarithm (d) of the reciprocal of .
  • the polymer compound used herein is synthesized by polymerizing an amino functional group-containing monomer containing an amino functional group or a salt thereof, or by a condensation reaction or transesterification of a polymer having a hydroxyl group and an amino functional group-containing monomer.
  • pKa1 is defined as the acid dissociation constant of the conjugate acid of an amine in a monomer containing an amino functional group or a salt thereof that is a component of a polymer compound.
  • pKa1 of a monomer containing an amino functional group or a salt thereof that is a constituent element of a polymer compound is referred to as "pKa1 of a polymer compound.”
  • the monomer containing the amino functional group or its salt, which is a component of the polymer compound is a polyvalent amine
  • the conjugate acid of the polyvalent amine undergoes ionization in multiple stages
  • pKa1 is the ionization constant of the first stage. It refers to pKa calculated based on.
  • the pKa1 of a polymer compound at 25°C is a value measured by titration. Specifically, titration is performed at 25°C using the hydrochloride of an amino functional group-containing monomer, which is a constituent element of a polymer compound, and sodium hydroxide, and the titration is carried out at the half-equivalence point (half the amount at which neutralization is completed). pKa1 can be determined by measuring the pH at 25° C. at the point where the solution was dropped. When the amino functional group-containing monomer is a free amine, pKa1 can be determined by the method described above after converting it into a hydrochloride.
  • an amino functional group-containing monomer is mixed with a 1 mol% hydrochloric acid aqueous solution, all of the amino groups contained in the amino functional group-containing monomer are converted to hydrochloride, and then frozen.
  • Examples include a method of removing hydrochloric acid and water by a general-purpose method such as drying.
  • the polymer compound does not contain an aromatic ring in the molecule. If the polymer compound does not contain an aromatic ring, whitening of the surface of the substrate can be generally prevented even when the substrate contains a virus infection inhibitor. Furthermore, if the polymer compound does not contain an aromatic ring, the bulk of the polymer compound will be reduced, allowing the molecular structure containing the amino functional group to efficiently interact with the virus, which will result in an excellent virus. Demonstrates infection prevention effect.
  • the aromatic ring includes not only a monocyclic aromatic ring but also a fused aromatic ring formed by condensing a complex of monocyclic aromatic rings.
  • the aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, biphenyl, and phenoxyphenyl.
  • the aromatic ring has one or more hydrogen atoms removed (extracted) from the aromatic ring and the fused aromatic ring, and is bonded to other atoms through covalent bonds.
  • the polymer compound is preferably formed in the form of particles because it can be uniformly dispersed on the surface of the substrate and can impart an excellent virus infection inhibiting effect to the substrate.
  • the D90 particle diameter of the polymer compound is preferably 1 ⁇ m or more, more preferably 2 ⁇ m or more, preferably 2.5 ⁇ m or more, more preferably 3 ⁇ m or more, and even more preferably 3.5 ⁇ m or more.
  • the D90 particle diameter of the polymer compound is preferably 50 ⁇ m or less, more preferably 25 ⁇ m or less, preferably 22 ⁇ m or less, more preferably 20 ⁇ m or less, more preferably 18 ⁇ m or less, more preferably 16 ⁇ m or less, more preferably 14 ⁇ m or less, and 12 ⁇ m or less.
  • the D90 particle size is 1 ⁇ m or more, the surface area of the entire polymer compound becomes small, the agglomeration of the virus infection inhibitor is reduced, and the polymer compound and the virus are in a form where it is easy to interact with each other.
  • the virus infection inhibiting effect is improved, and even when the base material contains the virus infection inhibiting effect, whitening of the surface of the base material can be generally prevented.
  • the D90 particle size is 50 ⁇ m or less, it is possible to prevent the aggregation of the virus infection inhibitor and increase the surface area to facilitate contact with the virus, thereby improving the virus infection prevention effect of the virus infection prevention member. Even when the base material contains a virus infection inhibiting effect, whitening of the surface of the base material can be generally prevented.
  • the D90 particle size of a polymer compound is the particle size (90% cumulative particle size) at which the cumulative frequency (accumulation from particles with small particle size) in the volume-based particle size distribution determined by the laser scattering method is 90%. ).
  • the D90 particle diameter of the polymer compound is a value measured based on the entire polymer compound.
  • the virus infection inhibitor may be used by being attached (supported) on the surface of the base particles. By attaching the virus infection inhibitor to the surface of the base particles, the virus infection inhibitor can be more uniformly dispersed in the base material, and whitening of the base material can be more effectively prevented. Furthermore, the surface area of the virus infection inhibitor can be increased, sufficient contact between the virus infection inhibitor and the virus can be ensured, and the virus infection inhibiting effect of the virus infection inhibitor can be fully exhibited.
  • the base particles to which the virus infection inhibitor is attached are not particularly limited as long as they do not inhibit the virus infection inhibiting effect of the virus infection inhibitor.
  • the base particles include resin particles and inorganic particles.
  • the base particles may be used alone or in combination of two or more types.
  • Examples of the synthetic resin constituting the resin particles include styrene resin, acrylic resin, urethane resin, vinyl chloride resin, ABS resin; styrene-butadiene rubber (SBR), nitrile-butadiene rubber (NBR), etc. Synthetic rubbers may be mentioned, with styrene resins and acrylic resins being preferred.
  • Styrenic resins are not particularly limited, and examples include homopolymers or copolymers containing styrene monomers as monomer units, such as styrene, methylstyrene, ethylstyrene, i-propylstyrene, dimethylstyrene, chlorostyrene, and bromostyrene. Examples include copolymers containing, as monomer units, a styrene monomer and one or more vinyl monomers copolymerizable with the styrene monomer.
  • vinyl monomers copolymerizable with styrene monomers include acrylonitrile, methacrylonitrile, acrylic acid, methacrylic acid, acrylic esters (methyl acrylate, ethyl acrylate, butyl acrylate, etc.), methacrylic esters (methacrylic acid Acrylic monomers such as methyl methacrylate, ethyl methacrylate, butyl methacrylate, maleic anhydride, acrylamide, etc.
  • the acrylic resin is not particularly limited, and includes, for example, a homopolymer containing an acrylic monomer such as methyl (meth)acrylate, ethyl (meth)acrylate, butyl (meth)acrylate, or pentyl (meth)acrylate as a monomer unit; Examples include copolymers, copolymers containing as monomer units an acrylic monomer and one or more vinyl monomers copolymerizable with the acrylic monomer. Note that (meth)acrylate means acrylate or methacrylate.
  • vinyl monomers that can be copolymerized with acrylic monomers include acrylonitrile, methacrylonitrile, maleic anhydride, and acrylamide.
  • the inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, magnesium hydroxide, and the like.
  • the synthetic resin constituting the resin particles contains an aromatic ring.
  • the aromatic ring attracts the hydrophobic part of the polymer compound attached to the surface of the resin particle and has the effect of orienting the amino functional group and carboxy group outward, thereby enhancing the virus infection inhibiting effect of the virus infection inhibitor. It can be used more effectively.
  • the aromatic ring may be a monocyclic aromatic ring or a complex of monocyclic aromatic rings condensed (fused aromatic ring).
  • the aromatic ring is not particularly limited, and examples thereof include a benzene ring, a naphthalene ring, an anthracene ring, biphenyl, and phenoxyphenyl.
  • the aromatic ring has one or more hydrogen atoms removed (extracted) from the aromatic ring and the fused aromatic ring, and is bonded to other atoms through covalent bonds.
  • the amount of the polymer compound attached to the resin particles is preferably 1 part by mass or more, more preferably 5 parts by mass or more, more preferably 7 parts by mass or more, and more preferably 10 parts by mass or more based on 100 parts by mass of the resin particles.
  • the virus infection inhibitor can be uniformly attached to the surface of the resin particles, and the virus infection inhibiting effect of the virus infection inhibitor can be more effectively exhibited. I can do it.
  • the amount of the polymer compound attached to the resin particles is preferably 1000 parts by mass or less, more preferably 800 parts by mass or less, more preferably 600 parts by mass or less, and more preferably 400 parts by mass or less based on 100 parts by mass of the resin particles.
  • the amount of the polymer compound attached is 1000 parts by mass or less, the virus infection inhibitors are not bonded to each other, and the virus infection inhibitors are efficiently disposed on the resin particle surface, improving the virus infection inhibiting effect.
  • the method of adhering the virus infection inhibitor to the surface of the resin particles is not particularly limited, and for example, the adhesive force of the virus infection inhibitor may be used, or the virus infection inhibitor may be adhered to the surface of the resin particles using a binder resin.
  • the polymer compound is attached to the surface of the resin particles by the adhesive force of the polymer compound itself, so that the virus infection inhibiting effect of the virus infection inhibitor can be effectively exhibited. .
  • the virus infection inhibitor has a virus infection inhibiting effect against various viruses through the action of a polymer compound, and exhibits an excellent virus infection inhibiting effect against both enveloped viruses and non-enveloped viruses.
  • enveloped viruses examples include influenza viruses (e.g., type A, type B, etc.), rubella virus, Ebola virus, coronaviruses (e.g., SARS virus, new coronavirus (SARS-CoV-2)), measles virus, varicella virus, etc.
  • Herpes zoster virus herpes simplex virus, mumps virus, arbovirus, respiratory syncytial virus, hepatitis virus (e.g., hepatitis B virus, hepatitis C virus, etc.), yellow fever virus, AIDS virus, rabies virus, hantavirus, dengue virus, Nipah virus , lyssavirus, etc.
  • non-enveloped viruses examples include feline calicivirus, adenovirus, norovirus, rotavirus, human papillomavirus, poliovirus, enterovirus, coxsackievirus, human parvovirus, encephalomyocarditis virus, and rhinovirus.
  • the virus infection inhibiting agent can be incorporated into the base material described below to constitute a virus infection inhibiting member, and can impart an excellent virus infection inhibiting effect to the base material without substantially causing whitening on the surface of the base material. I can do it.
  • the base material containing the virus infection inhibitor is not particularly limited as long as it is desired to impart a virus infection inhibiting effect, and examples include paints, synthetic resin moldings, wallpaper, decorative sheets, flooring materials, textile products (textiles , non-woven fabrics, knitted fabrics), interior products and interior materials for vehicles (e.g. cars, airplanes, ships, etc.) (seats, child seats and the foam materials that make up these, etc.), kitchen products, baby products, architectural interior materials Examples include.
  • Architectural interior materials are not particularly limited, and include, for example, flooring materials, wallpaper, ceiling materials, paints, doorknobs, switches, switch covers, wax, and the like.
  • Vehicle interior supplies and vehicle interior materials are not particularly limited, and include, for example, seats, child seats, seat belts, car mats, seat covers, doors, ceiling materials, floor mats, door trims, instrument panels, consoles, glove boxes, hanging leather, handrails, etc. can be mentioned.
  • the content of the polymer compound in the base material is preferably 0.1 part by mass or more, more preferably 0.5 part by mass or more, more preferably 1 part by mass or more, and 2 parts by mass based on 100 parts by mass of the base material. The above is more preferable.
  • the content of the polymer compound in the base material is preferably 30 parts by mass or less, more preferably 20 parts by mass or less, more preferably 10 parts by mass or less, and more preferably 7 parts by mass or less based on 100 parts by mass of the base material. .
  • the content of the polymer compound in the base material is 0.1 parts by mass or more, the virus infection inhibiting effect of the virus infection inhibiting member can be improved.
  • the content of the polymer compound in the base material is 30 parts by mass or less, the polymer compound does not aggregate and is easily dispersed uniformly without affecting the physical properties of the base material, thereby improving the effect of inhibiting virus infection. will improve.
  • the virus infection inhibiting agent constitutes a virus infection inhibiting paint by including it in the paint.
  • a coating film formed from a virus infection inhibiting paint exhibits an excellent virus infection inhibiting effect, and whitening of the coating film surface is generally prevented, making it possible to form a coating film with excellent appearance.
  • the paint As the paint, a conventionally known paint is used.
  • the paint has improved dispersibility of the virus infection inhibitor, can form a coating film having an excellent virus infection inhibiting effect, and can be used as both a hydrophobic paint and a hydrophilic paint.
  • the hydrophobic paint is not particularly limited, and includes, for example, oil-based paints (eg, blended paints, oil varnishes, etc.), cellulose paints, synthetic resin paints, and the like. Paints also include photocurable paints that polymerize to produce a binder component when irradiated with radiation such as ultraviolet rays.
  • the water-based paint is not particularly limited, and examples thereof include water-based urethane paint, water-based silicone paint, water-based fluorine paint, and water-based inorganic paint.
  • the paint may contain a solvent to adjust the viscosity.
  • a solvent an organic solvent is preferable because it improves the dispersibility of the virus infection inhibitor in the paint.
  • the organic solvent is not particularly limited, and examples thereof include toluene, xylene, methyl ethyl ketone, acetone, ethyl acetate, benzene, and isopropyl alcohol. Note that the solvents may be used alone or in combination of two or more.
  • the content of the polymer compound in the virus infection inhibiting paint is preferably 1% by mass or more, more preferably 2% by mass or more.
  • the content of the polymer compound in the virus infection inhibiting paint is preferably 10% by mass or less, more preferably 7% by mass or less, and even more preferably 5% by mass or less.
  • the coating film formed from the virus infection inhibiting paint exhibits an excellent virus infection inhibiting effect.
  • the content of the polymer compound is 10% by mass or less, the polymer compound does not aggregate and is easily dispersed uniformly, which improves the effect of inhibiting virus infection and makes it difficult to affect the physical properties of the base material, which is preferable. .
  • paints may contain additives such as pigments, plasticizers, curing agents, extenders, fillers, anti-aging agents, thickeners, surfactants, etc., as long as they do not impair their physical properties. good.
  • Examples of methods for incorporating the virus infection inhibitor into the paint include a method in which the virus infection inhibitor and paint are supplied to a dispersion device and mixed uniformly.
  • examples of the dispersion device include a high-speed mill, a ball mill, and a sand mill.
  • Polymer compounds 1 to 16 were prepared.
  • Polymer compound ⁇ Polymer compound 1 [polymer compound having a repeating unit represented by formula (1)] A polymer compound commercially available from Nittobo Medical Co., Ltd. under the trade name "PAA-15C" was freeze-dried to obtain a powder of polymer compound 1.
  • m, n, and p represent repeating units, and all are natural numbers of 2 or more.
  • x is a natural number of 2 or more.
  • the structural formula expressed as formula (8) means a random copolymer, alternating copolymer, or block copolymer of monomer unit M 1 and monomer unit M 2 .
  • Table 1 shows the nitrogen atom content, weight average molecular weight Mw, pH of a 5% by mass aqueous solution at 25°C, and pKa1 at 25°C for the polymer compounds used in Examples and Comparative Examples.
  • pH of a 5% by mass aqueous solution at 25°C and pKa1 at 25°C are simply written as “pH” and "pKa1", respectively.
  • Examples 1 to 10 and Comparative Examples 1 to 6 A virus infection inhibitor containing 5 parts by mass of particles of the polymer compound shown in Table 1 prepared in the manner described above, and 95 parts by mass of ultraviolet curable acrylic paint (trade name "AI-N2" manufactured by Coattec Co., Ltd.). A paint for preventing virus infection was prepared by mixing the two. The virus infection inhibiting paint was applied onto a polyethylene film to a thickness of 18 ⁇ m using a wire bar coater #8 to form a coating layer.
  • the UV-curable acrylic paint was cured by irradiating the coating layer with ultraviolet rays with a wavelength of 365 nm at a cumulative light intensity of 500 mJ/cm 2 at 25°C using a UV conveyor device (“ECS301G1” manufactured by Eye Graphics). A coating film having a thickness of 18 ⁇ m was formed.
  • the antiviral properties and whitening properties of the viral infection inhibitors were measured in the following manner, and the results are shown in Table 1.
  • test piece was prepared by cutting out a planar square shape with each side of 5.0 cm.
  • the surface of the coating film of the obtained test piece was wiped 10 times with a square-shaped nonwoven fabric (manufactured by Nippon Paper Crecia Co., Ltd., trade name "Kimwipe S-200") having a side of 10 cm to obtain a test coating film.
  • a square-shaped nonwoven fabric manufactured by Nippon Paper Crecia Co., Ltd., trade name "Kimwipe S-200" having a side of 10 cm to obtain a test coating film.
  • test coating was subjected to an antiviral test for feline calicivirus and influenza virus (test time: 24 hours) in accordance with ISO21702. After the reaction, the virus infectivity of the test coating was calculated using the plaque method for the virus suspension.
  • a blank coating film was prepared in the same manner as above except that no virus infection inhibitor was contained, and based on this blank coating, the virus infection titer (common logarithm value) (PFU/cm 2 ) was determined in the same manner as above. was calculated.
  • the virus infectivity titer (common logarithmic value) of the blank coating film was 6.5 PFU/cm 2 .
  • the antiviral activity value was calculated by subtracting the virus infection titer of the test coating from the virus infection titer of the blank coating.
  • Whitening property evaluation was conducted in accordance with JIS A 1454 Polymer-based Floor Material Test Method Stain Resistance Test.
  • 2 ml of purified water was dropped onto the surface of the test coating film, covered with a watch glass, and allowed to stand for 24 hours. Thereafter, it was removed with a household neutral detergent, and the surface was further wiped with industrial alcohol, and left to stand in a test room for 1 hour.
  • the haze of the coating film was evaluated in accordance with JIS K 7361.
  • the haze value (%) was measured using a haze meter (trade name: HM-150, manufactured by Murakami Color Research Institute) at a room temperature of 25° C. and a relative humidity of 40%. The larger the haze value, the greater the degree of whitening of the coating surface.
  • the virus infection inhibitor of the present invention can be incorporated into base materials such as paint films, wallpapers, decorative sheets, flooring materials, textile products, interior and interior materials for vehicles, kitchen products, baby products, and architectural interior materials. Even if the surface of the base material is contaminated, whitening of the surface of the base material can be generally prevented, and a virus infection prevention member having an excellent virus infection prevention effect and an excellent appearance can be constructed.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paints Or Removers (AREA)

Abstract

La présente invention concerne un inhibiteur d'infection virale capable d'empêcher largement le blanchiment d'une surface de matériau de base même lorsque l'inhibiteur d'infection virale est contenu dans le matériau de base et utilisé. L'inhibiteur d'infection virale de la présente invention est caractérisé en ce qu'il contient un composé polymère qui a au moins un groupe amino choisi dans le groupe constitué par un groupe amino primaire, un groupe amino secondaire et un groupe amino tertiaire, ou un sel de ceux-ci et a une masse moléculaire moyenne en poids de 1000 ou plus, la chaîne principale du composé polymère ne contenant pas d'atome d'azote. Par conséquent, l'inhibiteur d'infection virale peut empêcher largement le blanchiment d'une surface de matériau de base même lorsque l'inhibiteur d'infection virale est contenu dans le matériau de base et utilisé, et un élément d'inhibition d'infection virale qui présente d'excellents effets d'inhibition d'infection virale et présente un excellent aspect peut être configuré.
PCT/JP2023/007992 2022-03-25 2023-03-03 Inhibiteur d'infection virale, élément d'inhibition d'infection virale et peinture d'inhibition d'infection virale WO2023181844A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-049777 2022-03-25
JP2022049777 2022-03-25

Publications (1)

Publication Number Publication Date
WO2023181844A1 true WO2023181844A1 (fr) 2023-09-28

Family

ID=88100710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/007992 WO2023181844A1 (fr) 2022-03-25 2023-03-03 Inhibiteur d'infection virale, élément d'inhibition d'infection virale et peinture d'inhibition d'infection virale

Country Status (2)

Country Link
TW (1) TW202348138A (fr)
WO (1) WO2023181844A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286225A1 (en) * 2004-12-30 2008-11-20 Lars Schonemyr Antimicrobial and Antiviral Product
WO2017171066A1 (fr) * 2016-03-31 2017-10-05 積水化学工業株式会社 Composition antibactérienne et antivirale
JP2018002597A (ja) * 2016-06-27 2018-01-11 日華化学株式会社 抗ウイルス剤及び抗ウイルス性繊維製品
WO2020158632A1 (fr) * 2019-01-28 2020-08-06 久保田　徹 Eau fonctionnelle
WO2021022290A1 (fr) * 2019-07-29 2021-02-04 The Procter & Gamble Company Composition désinfectante

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286225A1 (en) * 2004-12-30 2008-11-20 Lars Schonemyr Antimicrobial and Antiviral Product
WO2017171066A1 (fr) * 2016-03-31 2017-10-05 積水化学工業株式会社 Composition antibactérienne et antivirale
JP2018002597A (ja) * 2016-06-27 2018-01-11 日華化学株式会社 抗ウイルス剤及び抗ウイルス性繊維製品
WO2020158632A1 (fr) * 2019-01-28 2020-08-06 久保田　徹 Eau fonctionnelle
WO2021022290A1 (fr) * 2019-07-29 2021-02-04 The Procter & Gamble Company Composition désinfectante

Also Published As

Publication number Publication date
TW202348138A (zh) 2023-12-16

Similar Documents

Publication Publication Date Title
JP2003027009A5 (fr)
Wang et al. Surface modification of hydroxyapatite with poly (methyl methacrylate) via surface-initiated ATRP
JP7406679B2 (ja) ウイルス感染阻止剤及びウイルス感染阻止製品
US20120149814A1 (en) Ultrahydrophobic coating and method for making the same
JP2013193966A (ja) 樹脂組成物、樹脂溶液、積層体及び樹脂シート
JP5780285B2 (ja) 紫外線散乱剤及びその用途
JP2011020993A (ja) Ｒｎａウイルス感染阻止成形用組成物及びｒｎａウイルス感染阻止成形品
WO2015178248A1 (fr) Film monocouche hydrophile
JP2011136977A (ja) Ｒｎａウイルス感染阻止塗料用組成物、ｒｎａウイルス感染阻止塗料及びｒｎａウイルス感染阻止製品
WO2023181844A1 (fr) Inhibiteur d'infection virale, élément d'inhibition d'infection virale et peinture d'inhibition d'infection virale
JP7406678B2 (ja) ウイルス感染阻止粒子及びウイルス感染阻止製品
Srivastava Co-polymerization of Acrylates
JPH07286129A (ja) コーティング用水系分散体
JP2012126677A (ja) インフルエンザウイルス感染阻止剤、インフルエンザウイルス感染阻止塗料及びインフルエンザウイルス感染阻止製品
Bamane et al. Development of a water-based functional additive by using isobornyl acrylate copolymer to improve ink-adhesion on untreated polypropylene surfaces: A comparative approach
WO2023171555A1 (fr) Agent inhibiteur d'infection virale, particules inhibitrices d'infection virale, et matériau de revêtement inhibiteur d'infection virale
JP2023142828A (ja) ウイルス感染阻止剤、ウイルス感染阻止粒子及びウイルス感染阻止塗料
WO2024034650A1 (fr) Agent inhibiteur d'infection virale, composition de résine, et produit inhibiteur d'infection virale
JP2023067367A (ja) ウイルス感染阻止剤及びウイルス感染阻止製品
WO2023171557A1 (fr) Élément d'inhibition d'infection virale
WO2023074805A1 (fr) Inhibiteur d'infection virale et produit inhibiteur d'infection virale
Suma et al. Paint formulation using water based binder and property studies
WO2024043320A1 (fr) Inhibiteur d'infection virale, produit d'inhibition d'infection virale et procédé de fabrication de produit d'inhibition d'infection virale
WO2024053654A1 (fr) Inhibiteur d'infection virale, composition de résine, mélange maître pour moulage de résine synthétique, et produit d'inhibition d'infection virale
WO2024034647A1 (fr) Agent antibactérien et antiviral, composition de résine et élément antibactérien et antiviral

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2023519431

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23774443

Country of ref document: EP

Kind code of ref document: A1